deCODE genetics/Amgen, Reykjavik, Iceland
Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Ann Rheum Dis. 2022 Aug;81(8):1085-1095. doi: 10.1136/annrheumdis-2021-221754. Epub 2022 Apr 25.
To find causal genes for rheumatoid arthritis (RA) and its seropositive (RF and/or ACPA positive) and seronegative subsets.
We performed a genome-wide association study (GWAS) of 31 313 RA cases (68% seropositive) and ~1 million controls from Northwestern Europe. We searched for causal genes outside the HLA-locus through effect on coding, mRNA expression in several tissues and/or levels of plasma proteins (SomaScan) and did network analysis (Qiagen).
We found 25 sequence variants for RA overall, 33 for seropositive and 2 for seronegative RA, altogether 37 sequence variants at 34 non-HLA loci, of which 15 are novel. Genomic, transcriptomic and proteomic analysis of these yielded 25 causal genes in seropositive RA and additional two overall. Most encode proteins in the network of interferon-alpha/beta and IL-12/23 that signal through the JAK/STAT-pathway. Highlighting those with largest effect on seropositive RA, a rare missense variant in (rs140675301-A) that is independent of reported non-coding -variants, increases the risk of seropositive RA 2.27-fold (p=2.1×10), more than the rs2476601-A missense variant in (OR=1.59, p=1.3×10). rs140675301-A replaces hydrophilic glutamic acid with hydrophobic valine (Glu128Val) in a conserved, surface-exposed loop. A stop-mutation (rs76428106-C) in increases seropositive RA risk (OR=1.35, p=6.6×10). Independent missense variants in (rs34536443-C, rs12720356-C, rs35018800-A, latter two novel) associate with decreased risk of seropositive RA (ORs=0.63-0.87, p=10-10) and decreased plasma levels of interferon-alpha/beta receptor 1 that signals through TYK2/JAK1/STAT4.
Sequence variants pointing to causal genes in the JAK/STAT pathway have largest effect on seropositive RA, while associations with seronegative RA remain scarce.
寻找类风湿关节炎(RA)及其血清阳性(RF 和/或 ACPA 阳性)和血清阴性亚组的因果基因。
我们对来自西北欧的 31313 例 RA 病例(68%血清阳性)和约 100 万对照进行了全基因组关联研究(GWAS)。我们通过对编码的影响、几种组织中的 mRNA 表达和/或血浆蛋白水平(SomaScan)寻找 HLA 基因座外的因果基因,并进行了网络分析(Qiagen)。
我们发现 31313 例 RA 患者中有 25 个序列变异,33 个为血清阳性 RA,2 个为血清阴性 RA,34 个非 HLA 基因座中有 37 个序列变异,其中 15 个是新的。对这些基因进行基因组、转录组和蛋白质组分析,得到了 25 个血清阳性 RA 的因果基因,另外还有 2 个总的因果基因。大多数编码干扰素-α/β和 IL-12/23 信号通过 JAK/STAT 通路的网络中的蛋白质。突出那些对血清阳性 RA 影响最大的,是位于 (rs140675301-A)中的一个罕见错义变异,它独立于报道的非编码 - 变异,使血清阳性 RA 的风险增加 2.27 倍(p=2.1×10),超过了位于 (OR=1.59,p=1.3×10)中的 rs2476601-A 错义变异。rs140675301-A 将亲水性谷氨酸替换为保守的、表面暴露的环中的疏水性缬氨酸(Glu128Val)。位于 (rs76428106-C)中的一个终止突变增加了血清阳性 RA 的风险(OR=1.35,p=6.6×10)。位于 (rs34536443-C、rs12720356-C、rs35018800-A,后两者为新发现)中的独立错义变异与血清阳性 RA 的风险降低相关(ORs=0.63-0.87,p=10-10),并降低了通过 TYK2/JAK1/STAT4 信号传导的干扰素-α/β受体 1 的血浆水平。
指向 JAK/STAT 通路中因果基因的序列变异对血清阳性 RA 的影响最大,而与血清阴性 RA 的关联仍然很少。